Stock DIM SARTORIUS STEDIM BIOTECH
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sartorius Stedim Biotech

Equities

DIM

FR0013154002

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris
Other stock markets
 11:35:08 2024-04-26 EDT 		5-day change 1st Jan Change
208.3 EUR +2.41% Intraday chart for Sartorius Stedim Biotech +3.84% -13.03%
04-23 SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating ZD
04-22 Sartorius Stedim: in the red with brokerage comments CF

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 13,615 26,843 44,467 27,883 22,073 20,270 - -
Enterprise Value (EV) 1 13,723 27,370 44,869 28,912 25,638 22,535 22,424 22,065
P/E ratio 58.1 x 75.1 x 107 x 31.8 x 71.3 x 57.7 x 41.7 x 32.8 x
Yield 0.46% 0.23% 0.26% 0.48% - 0.36% 0.53% 0.65%
Capitalization / Revenue 9.45 x 14.1 x 15.4 x 7.98 x 7.95 x 6.89 x 6.05 x 5.37 x
EV / Revenue 9.53 x 14.3 x 15.5 x 8.28 x 9.24 x 7.66 x 6.69 x 5.85 x
EV / EBITDA 32.6 x 45.3 x 43.4 x 23.7 x 32.6 x 25.3 x 21.1 x 17.6 x
EV / FCF 78.8 x 106 x 121 x 159 x - 74.4 x 67.7 x 50.1 x
FCF Yield 1.27% 0.94% 0.83% 0.63% - 1.34% 1.48% 2%
Price to Book 11.7 x 18.4 x 26.9 x 11.4 x - 4.89 x 4.61 x 4.12 x
Nbr of stocks (in thousands) 92,180 92,180 92,179 92,177 92,163 97,311 - -
Reference price 2 147.7 291.2 482.4 302.5 239.5 208.3 208.3 208.3
Announcement Date 20-01-28 21-02-18 22-01-27 23-01-26 24-01-26 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,441 1,910 2,887 3,493 2,776 2,940 3,350 3,774
EBITDA 1 421.5 604.7 1,033 1,221 785.4 890.7 1,065 1,253
EBIT 1 332 471.8 865.4 1,040 - 660 806.5 977.7
Operating Margin 23.05% 24.7% 29.98% 29.77% - 22.45% 24.07% 25.9%
Earnings before Tax (EBT) 1 317.6 482.6 646.7 1,130 - 484.1 695.7 881.5
Net income 1 234.6 357.8 414.4 876.1 309.7 343.3 458.9 578.1
Net margin 16.28% 18.73% 14.35% 25.08% 11.16% 11.68% 13.7% 15.32%
EPS 2 2.540 3.880 4.500 9.510 3.360 3.607 5.000 6.358
Free Cash Flow 1 174.2 257.7 372 181.7 - 302.7 331.4 440.6
FCF margin 12.09% 13.49% 12.88% 5.2% - 10.3% 9.89% 11.67%
FCF Conversion (EBITDA) 41.32% 42.62% 36% 14.88% - 33.99% 31.13% 35.15%
FCF Conversion (Net income) 74.24% 72.03% 89.76% 20.74% - 88.19% 72.23% 76.22%
Dividend per Share 2 0.6800 0.6800 1.260 1.440 - 0.7461 1.101 1.348
Announcement Date 20-01-28 21-02-18 22-01-27 23-01-26 24-01-26 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S2 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - 1,352 757 779 - 862.5 861.8 878.4 890 726.1 675.7 666.9 706.8 666.9 706.1 748.1 796.8 -
EBITDA 1 - - 487.4 278.1 267.9 - 303.7 303.3 304.9 309.5 220.1 195.6 178.3 191.4 191 208.3 229.8 262 -
EBIT 1 164.8 265.3 - 238.7 221.4 451.3 263 260.6 262.7 253.4 171.5 145.2 76.9 - 120.6 167.5 189 221 -
Operating Margin - - - 31.53% 28.42% - 30.49% 30.24% 29.91% 28.47% 23.62% 21.49% 11.53% - 18.08% 23.72% 25.26% 27.74% -
Earnings before Tax (EBT) 1 - - - 209.5 63.82 - 337.8 283.2 273.5 235.9 148.6 158.9 35.5 - 77 140.5 162 195.5 -
Net income 1 - - - 147.7 8.213 - 270.1 214.8 204.5 186.7 111.1 133.1 25.7 39.8 56.1 78.65 94.57 125.5 -
Net margin - - - 19.51% 1.05% - 31.32% 24.92% 23.28% 20.98% 15.3% 19.7% 3.85% 5.63% 8.41% 11.14% 12.64% 15.75% -
EPS 2 - - - 1.600 0.0900 - 2.930 2.330 2.220 2.030 1.210 1.440 0.2800 0.4300 0.5800 0.8081 0.9717 1.289 -
Dividend per Share 2 - - - - 1.260 - - - - 1.440 - - - - 0.2393 0.2332 0.2332 0.2332 0.2938
Announcement Date 20-01-28 21-02-18 21-07-21 21-10-20 22-01-27 22-01-27 22-04-21 22-07-21 22-10-19 23-01-26 23-04-20 23-07-21 23-10-19 24-01-26 24-04-18 - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 108 527 402 1,029 3,565 2,265 2,154 1,795
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.2555 x 0.8715 x 0.3889 x 0.8421 x 4.539 x 2.543 x 2.023 x 1.432 x
Free Cash Flow 1 174 258 372 182 - 303 331 441
ROE (net income / shareholders' equity) 21.4% 27.3% 26.8% 42.7% - 13.4% 14.4% 16%
ROA (Net income/ Total Assets) 13.8% 15.6% 12.2% 19.4% - 5.53% 6.39% 7.51%
Assets 1 1,696 2,291 3,404 4,509 - 6,208 7,184 7,703
Book Value Per Share 2 12.60 15.80 18.00 26.60 - 42.60 45.20 50.60
Cash Flow per Share 2 3.360 4.520 7.550 6.640 - 5.540 7.780 9.450
Capex 1 136 159 324 431 474 374 345 368
Capex / Sales 9.44% 8.33% 11.22% 12.33% 17.06% 12.74% 10.31% 9.76%
Announcement Date 20-01-28 21-02-18 22-01-27 23-01-26 24-01-26 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Sartorius Stedim Biotech

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
208.3 EUR
Average target price
251.3 EUR
Spread / Average Target
+20.66%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
SARTORIUS STEDIM BIOTECH Stock Sartorius Stedim Biotech
-13.03% 21.64B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. DIM Stock
  4. Financials Sartorius Stedim Biotech